These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28089627)

  • 61. Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study.
    Agresti R; Sandri M; Gennaro M; Bianchi G; Maugeri I; Rampa M; Capri G; Carcangiu ML; Trecate G; Riggio E; Lozza L; de Braud F
    Clin Breast Cancer; 2017 Jun; 17(3):219-231. PubMed ID: 28087389
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease.
    Lee YC; Wu JS; Yang YC; Chang CS; Lu FH; Chang CJ
    Scand J Gastroenterol; 2014 Aug; 49(8):1001-6. PubMed ID: 24989169
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females.
    Wang L; Guo J; Lu J
    Oncotarget; 2016 Jun; 7(24):35632-35642. PubMed ID: 27248665
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
    Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Change of influence of prognostic markers on metastasis free interval during and after adjuvant tamoxifen therapy in breast cancer patients.
    Abu Rabi Z; Todorovic-Rakovic N; Markicevic M; Stamatovic L; Vujasinovic T; Nikolic-Vukosavljevic D
    J BUON; 2013; 18(2):321-7. PubMed ID: 23818341
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epidemiologic Association of Nonalcoholic Fatty Liver Disease and Urinary Calculi: a Population-based Cross-sectional Study in Southern China.
    Wei YP; Lin XG; He RQ; Shen J; Sun SL; Chen G; Wang QY; Xu JF; Mo ZN
    Iran J Kidney Dis; 2018 Mar; 12(2):112-119. PubMed ID: 29507274
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival.
    Taroeno-Hariadi KW; Putra YR; Choridah L; Widodo I; Hardianti MS; Aryandono T
    J Breast Cancer; 2021 Oct; 24(5):417-427. PubMed ID: 34652078
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery.
    Lee YS; Lee HS; Chang SW; Lee CU; Kim JS; Jung YK; Kim JH; Seo YS; Yim HJ; Lee CH; Woo SU; Seo JH; Yeon JE; Um SH; Byun KS
    Medicine (Baltimore); 2019 Sep; 98(39):e17277. PubMed ID: 31574842
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.
    Glassner K; Malaty HM; Abraham BP
    Inflamm Bowel Dis; 2017 Jun; 23(6):998-1003. PubMed ID: 28511199
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nonalcoholic Fatty Liver Disease Associated With Bladder Cancer.
    Chiang CL; Huang HH; Huang TY; Shih YL; Hsieh TY; Lin HH
    Am J Med Sci; 2020 Aug; 360(2):161-165. PubMed ID: 32448495
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity.
    Gu W; Xu W; Sun X; Zeng B; Wang S; Dong N; Zhang X; Chen C; Yang L; Chen G; Xin A; Ni Z; Wang J; Yang J
    Sci Rep; 2017 Mar; 7():43940. PubMed ID: 28266626
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease.
    Wei Z; Ren Z; Hu S; Gao Y; Sun R; Lv S; Yang G; Yu Z; Kan Q
    Cancer Med; 2020 Feb; 9(3):1254-1262. PubMed ID: 31860170
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Non-alcoholic fatty liver disease and colorectal cancer survival.
    Wu K; Zhai MZ; Weltzien EK; Cespedes Feliciano EM; Meyerhardt JA; Giovannucci E; Caan BJ
    Cancer Causes Control; 2019 Feb; 30(2):165-168. PubMed ID: 30443695
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey.
    Chang CF; Tseng YC; Huang HH; Shih YL; Hsieh TY; Lin HH
    Intern Emerg Med; 2018 Mar; 13(2):191-197. PubMed ID: 29235054
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Lee B; Jung EA; Yoo JJ; Kim SG; Lee CB; Kim YS; Jeong SW; Jang JY; Lee SH; Kim HS; Jun BG; Kim YD; Cheon GJ
    Liver Int; 2020 Jun; 40(6):1344-1355. PubMed ID: 32170895
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones.
    Pafili K; Paschou SA; Armeni E; Polyzos SA; Goulis DG; Lambrinoudaki I
    J Endocrinol Invest; 2022 Sep; 45(9):1609-1623. PubMed ID: 35303270
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the Clinical Practice Research Datalink.
    Florio AA; Graubard BI; Yang B; Thistle JE; Bradley MC; McGlynn KA; Petrick JL
    Eur J Epidemiol; 2019 Sep; 34(9):871-878. PubMed ID: 31165323
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage.
    Suwarto S; Diahtantri RA; Hidayat MJ; Widjaya B
    PLoS One; 2018; 13(10):e0205965. PubMed ID: 30332476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.